

HRP-220	002	21 Mar 2022	Page 1 of 6
Document No.:	Edition No.:	Effective Date:	Page:

Use this form to request a waiver to access an individual's Protected Health Information(PHI). The completed form must be reviewed and approved before any access to PHI.

Study Title:	
Principal Investigator:	
IRBNet #:	
Choose the option that a	pplies:
Pre-Screening of heal	th care records to identify possible subjects for recruitment purposes.
Complete section	ns "General Information" and "Partial Waiver of Authorization"
	obtain information that currently exists or will be collected in the future for a subject's written consent and authorization.
Complete section	ns "General Information" and "Waiver of Authorization"
	General Information
medications, la	b results, imaging, etc. (Specific identifiers will be checked below):
	urce of the health information (check all that apply): ventHealth Medical Group medical records rce of PHI:



HRP-220	002	21 Mar 2022	Page 2 of 6
Document No.:	Edition No.:	Effective Date:	Page:

3. Select all of the identifiers that will be	used in this research
Names	☐ Vehicle Identification/License Plate
	numbers
Addresses including ZIP	Account numbers
All date (except year) and ages over 89	Biometric identifiers
Telephone numbers	Device identifiers
Fax numbers	Full face photos & any comparable
	images
Social Security Numbers	URLS
Medical Record Numbers	IP Addresses
Health plan numbers	Email addresses
Certificate/License numbers	Any other unique identifying number,
	characteristic, or code (except those
	assigned by an investigator to code the
	data)
	uataj
Partial Waiv	er of Authorization
	rmation (PHI) involves no more than minimal risk to the
	of PHI in this research poses no greater than minimal risk
to participants' privacy.	
2. Describe the plan to protect identifiers and inc	dicate where PHI will be stored and who will have access
(list all entities that might have access to the F	PHI such as IRB, sponsors, FDA, data safety monitoring
boards, and anyothers given authority by law)	



Document No.:	Edition No.:	Effective Date:	Page:
HRP-220	002	21 Mar 2022	Page 3 of 6

4.	Recruitment for this research could not practicably be conducted without a partial waiver of authorization because:
5.	Recruitment for this research could not practicably be conducted without access to and use of the PHI because:
5.	
5.	
5.	
5.	



Document No.:	Edition No.:	Effective Date:	Page:
HRP-220	002	21 Mar 2022	Page 4 of 6

	waiver of Authorization
1.	The use or disclosure of Protected Health Information (PHI) involves no more than minimal risk to the privacy of individuals. Describe how the use of PHI in this research poses no greater than minimal risk
	to participants' privacy.
2.	Describe the plan the protect identifiers and indicate where PHI will be stored and who will have access (list all entities that might have access to the PHI such as IRB, sponsors, FDA, data safety monitoring boards, and anyothers given authority by law).



Document No.:	Edition No.:	Effective Date:	Page:
HRP-220	002	21 Mar 2022	Page 5 of 6

3.	Describe the plan to destroy the participant identifiers at the earliest opportunity consistent with the conduct of research, unless retention is required for reasons of health, research, or law. Please explain if the participant identifiers will be stored or retained and the length of time they will be stored or
	retained:
4.	The research could not practicably be conducted without the waiver because:
"	The recommendation production with the second control of the secon
5.	The research could not practicably be conducted without access to and use of the PHI because:
J.	The research could not practicably be conducted without access to and use of the Fill because.
1	



Document No.:	Edition No.:	Effective Date:	Page:
HRP-220	002	21 Mar 2022	Page 6 of 6

PI Assurances

In applying for a waiver of authorization or partial waiver of authorization, I agree to the following:

- A) The identifiers used for this research study will not be used for any other purpose or disclosed to any other person or entity (aside from members of the research team identified in the research application), except as required by law.
- B) If at any time I want to reuse this information for other purposes or disclose the information to other individuals, I will seek approval from the IRB.
- C) I will comply with AdventHealth HIPAA policies and procedures and with the use and disclosure restrictions describes above.

I assume responsibility for all uses and disclosures of the PHI by members of the study team.
Date:
Principal Investigator Signature: